Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Cash from Financing Activities: 2021-2025

Historic Cash from Financing Activities for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $100.0 million.

  • ARS Pharmaceuticals' Cash from Financing Activities rose 14612.50% to $100.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.4 million, marking a year-over-year increase of 5203.62%. This contributed to the annual value of $72.4 million for FY2024, which is 949.41% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Cash from Financing Activities of $100.0 million as of Q3 2025, which was up 3,609.49% from $2.7 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Cash from Financing Activities peaked at $193.8 million during Q4 2022, and registered a low of -$1.6 million during Q3 2022.
  • Over the past 3 years, ARS Pharmaceuticals' median Cash from Financing Activities value was $1.3 million (recorded in 2023), while the average stood at $16.6 million.
  • In the last 5 years, ARS Pharmaceuticals' Cash from Financing Activities crashed by 1,151.35% in 2022 and then soared by 14,612.50% in 2025.
  • ARS Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $52.8 million in 2021, then surged by 266.95% to $193.8 million in 2022, then plummeted by 99.07% to $1.8 million in 2023, then skyrocketed by 3,828.86% to $70.9 million in 2024, then soared by 14,612.50% to $100.0 million in 2025.
  • Its Cash from Financing Activities stands at $100.0 million for Q3 2025, versus $2.7 million for Q2 2025 and $725,000 for Q1 2025.